Swiftsure International Inc.
HOLMES BIOPHARMA – Eastern European Operation Awarded First Contract

Holmes Biopharma Inc. / Contract

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

HOLMES BIOPHARMA  –  Eastern European Operation Awarded First Contract

Scottsdale, Arizona – March 19, 2008 – Holmes Biopharma, Inc. (Symbol HHJA,
security code AOKDRX) announces the award of a first clinical trial
contract for their Kiev, Ukraine, Eastern European operation. The amount of
the contract is US$369,000.

Analysts, Frost & Sullivan predict that the market will be worth and
estimated  US$4.3 billion, by the end of 2008. This is primarily driven by
the increasing appeal of Eastern Europe to drug developers from both the US
and Western Europe. With a population in excess of 270 million, Eastern
Europe has a huge potential for clinical trials. According to Pharmafocus,
the number of clinical trials conducted in Eastern Europe has grown and
continues to grow at an average annual rate of 30%.
  
'This is a major accomplishment for Holmes Biopharma, given that our Kiev
operation is still in the early stages of development. We expect our
Eastern Eurpean operation to continue it’s steady growth.'  stated John
Metcalfe, President, Holmes Biopharma Inc.

About Holmes:
Holmes Biopharma Inc. is a contract research organization focused on
providing
integrated and cost effective clinical development services that help the
pharmaceutical
industry introduce new drug products rapidly from laboratory to the market.
It currently
has clinics in Omaha, Nebraska, Toronto, Canada and Kiev, Ukraine, Eastern
Europe For more information about the company please visit our website at
www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe, President and CEO, Holmes Biopharma Inc.

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:

www.holmesbiopharma.com
Tel: 1-800-778-4990 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
19.03.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------